These data further demonstrated a regulatory effect of Ikaros on both c-MYC and MYCBP2 in ALL patients and suggested that Ikaros deletion is one of the reasons for high c-MYC and low MYCBP2 expression in the patients. This evidence concerns the gene MYCBP2 and acute lymphoblastic leukemia.